Phentolamine: Difference between revisions

(Text replacement - "α 1" to "α<sub>1</sub>")
 
(3 intermediate revisions by one other user not shown)
Line 1: Line 1:
==Administration==
==Administration==
*Type: [[α<sub>1</sub> Blocker]]; Antidote, Extravasation; [[Antihypertensive]]
*Type: [[Alpha 1 Blocker]]; [[Antidote]], Extravasation; [[Antihypertensive]]
*Routes of Administration: IV, IM
*Routes of Administration: IV, IM
*Common Trade Names: OraVerse
*Common Trade Names: OraVerse
Line 29: Line 29:
*Hypersensitivity to phentolamine or components
*Hypersensitivity to phentolamine or components
*[[MI]]
*[[MI]]
*[[CAD]]
*CAD
*Angina
*Angina
*Caution if PUD
*Caution if PUD
Line 59: Line 59:


==Mechanism of Action==
==Mechanism of Action==
*[[α antagonist]]
*[[alpha 1 Blocker|α antagonist]]
 
==See Also==
*[[Vasopressors]]


==References==
==References==
<Epocrates, UpToDate>
<Epocrates, UpToDate>
[[Category:Pharmacology]]
[[Category:Pharmacology]]

Latest revision as of 10:38, 4 January 2022

Administration

Adult Dosing

  • Pheochromocytomectomy adjunct: 5mg IM/IV q2-4h PRN
    • Start: 1-2h preop
  • Extravasation (norepinephrine-associated): 5-10mg injected into affected area x1
    • Start: within 12h of extravasation

Pediatric Dosing

  • Pheochromocytomectomy adjunct: 1mg IM/IV q2-4h PRN
    • Start: 1-2h preop

Special Populations

Renal Dosing

  • No dosing adjustments

Hepatic Dosing

  • No dosing adjustments

Contraindications

  • Hypersensitivity to phentolamine or components
  • MI
  • CAD
  • Angina
  • Caution if PUD

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 19 minutes
  • Metabolism: Urine
  • Excretion: CYP450

Mechanism of Action

See Also

References

<Epocrates, UpToDate>